A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Authors
Keywords
-
Journal
Alzheimers Research & Therapy
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-27
DOI
10.1186/s13195-021-00843-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo tau pathology is associated with synaptic loss and altered synaptic function
- (2021) Emma M. Coomans et al. Alzheimers Research & Therapy
- The Role of Synaptic Dysfunction in Alzheimer’s Disease
- (2020) Yixuan (Amy) Pei et al. JOURNAL OF ALZHEIMERS DISEASE
- A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse
- (2020) Min Sung Gee et al. Alzheimers Research & Therapy
- Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
- (2020) Marta Milà‐Alomà et al. Alzheimers & Dementia
- Astrocytic p38α MAPK drives NMDA receptor-dependent long-term depression and modulates long-term memory
- (2019) Marta Navarrete et al. Nature Communications
- Neuronal p38α mediates age‐associated neural stem cell exhaustion and cognitive decline
- (2019) Leire Moreno‐Cugnon et al. AGING CELL
- Targeting the Synapse in Alzheimer’s Disease
- (2019) Johanna Jackson et al. Frontiers in Neuroscience
- Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy
- (2018) Ghazaleh Kheiri et al. REVIEWS IN THE NEUROSCIENCES
- Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers
- (2018) Matthew J. Huentelman et al. Frontiers in Aging Neuroscience
- An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease
- (2018) Philip Scheltens et al. Annals of Clinical and Translational Neurology
- Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
- (2018) Yu Chen et al. PHARMACOLOGY & THERAPEUTICS
- Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis
- (2018) Won Hwa Kim et al. NeuroImage-Clinical
- Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease
- (2017) Jong Kil Lee et al. MOLECULES
- Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers
- (2017) Kaitlin B. Casaletto et al. NEUROLOGY
- Tau association with synaptic vesicles causes presynaptic dysfunction
- (2017) Lujia Zhou et al. Nature Communications
- Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model
- (2017) E Lauretti et al. Translational Psychiatry
- Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production
- (2017) Sandra Colié et al. Scientific Reports
- The UPR and synaptic dysfunction in neurodegeneration
- (2016) Oliver J. Freeman et al. BRAIN RESEARCH
- Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
- (2016) Niklas Mattsson et al. EMBO Molecular Medicine
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
- (2016) Nicole Maphis et al. Alzheimers Research & Therapy
- Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer’s disease
- (2016) Peter Koppensteiner et al. Scientific Reports
- Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models
- (2015) Saktimayee M. Roy et al. ACS Chemical Neuroscience
- Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1
- (2015) Laura Schnöder et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus
- (2015) G. Aleph Prieto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss
- (2015) J H Birnbaum et al. Cell Death & Disease
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction
- (2013) D. Martin Watterson et al. PLoS One
- Soluble A Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors
- (2011) S. Li et al. JOURNAL OF NEUROSCIENCE
- Regulation of Tau Pathology by the Microglial Fractalkine Receptor
- (2010) Kiran Bhaskar et al. NEURON
- Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration
- (2010) Brian R. Hoover et al. NEURON
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders
- (2009) David M. Goldstein et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started